Barclays Adjusts Kura Oncology Price Target

Summary

Barclays has maintained Kura Oncology’s rating but adjusted the target price from $32.00 to $11.00. Kura Oncology, a clinical-stage biopharmaceutical company, is focused on developing targeted small molecule products for treating solid tumors and blood cancers, with tipifarnib as its main candidate.Stock Star

Impact Analysis

This event is at the company level, specifically affecting Kura Oncology. Barclays’ significant reduction in the target price suggests a negative outlook on the company’s future performance, possibly due to financial results or unmet expectations in product development. The company reported a quarterly loss of $57.43 million, with an EPS of -$0.66, worsening from -$0.59 previously, which could influence this decision.Reuters Investors may consider the risks of investing in Kura Oncology, given the adjusted expectations. The industry is competitive, with regulatory hurdles impacting potential drug approvals.Trading View